AzTrials
AzTrials

Rheumatoid ArthritisNECTARNCT06240299

Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR)

A study testing Neurofeedback in people with Rheumatoid Arthritis and Chronic Widespread Pain, run by NHS Greater Glasgow and Clyde at 1 site in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Rheumatoid arthritis is an autoimmune condition, causing inflammation and pain. Yet pain may persist even when inflammation has been treated. This residual pain, called nociplastic pain, has symptoms of a chronic pain condition called fibromyalgia. There are few effective therapies to address this residual pain. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Rheumatoid Arthritis, Chronic Widespread Pain
What is being tested?
Neurofeedback
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
16 participants
Where
1 siteUnited Kingdom
Study dates
24 Jun 2024to 29 Jan 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Fulfilment of the ACR/EULAR Classification Criteria for rheumatoid arthritis (RA)
  • Fulfilment of the American College of Rheumatology criteria for chronic widespread pain
  • Stable disease (swollen joint count ≤1 and CRP ≤10)
  • Has normal or corrected to normal vision and hearing abilities
  • Right-handed (to reduce baseline motor response test heterogeneity)
  • Pain intensity equal or larger than 4 on the Visual Numerical Scale (0 no pain, 10, max pain imaginable)

Who cannot join

  • Unable to understand the task.
  • Unable to provide a written informed consent.
  • Unable to understand English.
  • Major confounding neurological diseases including Multiple Sclerosis, Stroke, Traumatic Brain Injury, Parkinson's Disease, and Alzheimer's Disease)
  • Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in the study (psychosis, suicidal ideation etc)
  • Under active management of pain team (changing medications, other non pharmacological pain treatment)
  • Involved in other interventional experimental studies

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Aleksandra Vuckovic, PhD contact

+44 7906441955

aleksandra.vuckovic@glasgow.ac.uk

United Kingdom1 site, 1 recruiting
  • Clinical Research Facility (CRF), Queen Elizabeth University Hospital

    Glasgow, Scotland, G51 4LS

    Manager, +44141 232 7600, Glasgow.CRF@ggc.scot.nhs.uk

    Neil Basu, MD, PhD

    Recruiting

Other trials in United Kingdom

About this study

Official title: Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis

Rheumatoid arthritis is an autoimmune condition, causing inflammation and pain. Yet pain may persist even when inflammation has been treated. This residual pain, called nociplastic pain, has symptoms of a chronic pain condition called fibromyalgia. There are few effective therapies to address this residual pain. Published literature shows that fibromyalgia can be treated by neurofeedback, a noninvasive method that is based on the voluntary modulation of cortical activity. In this pilot study, the investigators want to test the effect of neurofeedback on the fibromyalgia component of pain in rheumatoid arthritis, and also to investigate its effects on related symptoms such as fatigue and sleep disturbance.

Read the detailed description

Study Schedule For each participant, the intervention paradigm consists of a 1-week diary of pain, sleep and fatigue prior to baseline assessment, 10 intervention sessions 2-3 times per week, post-intervention assessment and remote post-intervention follow-up interview, one month after the last intervention. Hence, each participant will be enrolled in the study for 11-13 weeks, including the follow-up assessment. In case of short-term health problems (e.g., Covid 19, flu, seasonal allergy, etc), experimental sessions can be postponed for up to one week. A maximum of two sessions can be missed otherwise participants will be withdrawn from the study.

Intervention EEG will be recorded with one unit (16 channels) of a modular EEG device (usbamp, Gtec, Austria) requiring 5-10 min setup. Before neurofeedback training (NF), daily baseline EEG activity will be recorded for 2 min, during which participants will sit in a relaxed state, with eyes open. After that, participants will see a graphical user interface (GUI) consisting of three bars that correspond to signal power in three frequency bands: theta, alpha and beta. The bars change colour and height proportionally to the band power. Participants will be aiming to decrease theta and beta and to increase alpha band power as compared to the baseline values. If the power of a particular band passes the threshold level set by the daily baseline recording, the corresponding column turns green, otherwise, the colour is red. NF will be provided from the sensorimotor cortex (electrode locations C4/C3). In total, each training session lasts for 30 min. A second, 2min long EEG recording in the relaxed state with eyes opened will be recorded immediately after the NF session. The experimenter will advise participants on successful mental strategies in the first 3 sessions and will let participants choose their preferred strategy during sessions 4-10.

Baseline EEG recording Participants will be comfortably sitting approximately 1 meter from a computer screen. EEG will be recorded with 4 units (64 channels, passive electrodes) of modular multichannel EEG. This setup requires up to 30 min. EEG will be recorded for 8 min in alternative 2 min blocks of relaxed eyes open and eyes closed state. During eyes open recording, they will be asked to look at a cross in the centre of the screen to avoid excessive eye movements. Following this, participants will be asked to perform cue-based motor imagination practice, i.e., to imagine moving their left and right hands and feet every time they see a cue on a computer screen. Cues will appear in semi-random order, each cue appearing 60 times. A total of 180 trials will be split in six sub-sessions, each totalling 30 trials (10 right hand, 10 left hand, 10 feet).

Quantitative Sensory Testing Quantitative Sensory Testing (QST) is a standardised methodology to study pain sensitivity in humans. A QST protocol includes a series of noxious and non-noxious stimuli delivered to a patient, followed by a semi-objective method for the patient to rate their perception of each stimulus. In this study, participants will complete an abbreviated QST battery to characterise pain sensitivity. All participants who consent to this procedure will undergo familiarisation training prior to data collection to reduce QST-related anxiety. QST comprise of pressure pain sensitivity test and cuff algometry test. Pressure pain sensitivity (15-20 minutes) will be assessed using a digital algometer with a 1 cm2 rubber probe to quantify pressure pain thresholds (PPT) at multiple body sites. Pressure will be manually increased up to 1000 kilo Pascals (kPa). Cuff algometry (10 minutes) will be used to measure deep muscle tonic pain. This consists of a computer controlled air compressor which delivers varying degrees of pressure to a Velcro-adjusted cuff applied to one gastrocnemius muscle.

Visit 1 (week 0): Screening, Consent, Baseline EEG , Questionnaires and Research assessments (including QST). The total duration of Visit 1 will be 4-5 hours including comfort breaks and time for EEG setup.

Visits 2-11 (weeks 1-5): Neurofeedback sessions 1-10, Pain questionnaires (structured and semi-structured). The study visit, including EEG setup (time to put it on and off), intervention and debriefing will take 60-70 min.

Visit 12 (week 6): post-intervention EEG, Questionnaires and Research assessments (including QST). This assessment will take place within 7 (±5) days after the last NF session. The total duration of Visit 12 will be 4-5 hours including comfort breaks and time for EEG setup.

Visit 13 (week 10): remote follow-up. A 10 min semi-structured interview, covering topics such as pain, sleep, fatigue and any adverse effects. The interview will take place over the phone.

Being tested
Neurofeedback
Medical subject headings
Arthritis, Rheumatoid, Chronic Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NeurofeedbackProcedure or surgery

    A noninvasive method based on the voluntary modulation of brain activity, with feedback provided through a graphical user interface shown on a computer screen

Study groups in NCT06240299
Study groupRoleWhat they receive
Rheumatoid Arthritis - neurofeedback trainingExperimentalIntervention: visual neurofeedback Research Assessments * EEG: relaxed state and motor imagery * Quantitative sensory testing Questionnaires (after each intervention session): * visual analog scale - rate pain intensity * pain description and pain intensity reporting * mental strategies, affects (emotional experience) and sensations during NF * adverse event reporting * NASA task load index Questionnaires (week before and week after intervention weeks) * Routine Assessment of Patient Index Data 3 (RAPID3) * American College of Rheumatology Fibromyalgia Scale (ACRFS) * McGill Pain Questionnaire * Patient-Reported Outcomes Measurement Information System (PROMIS) Depression * PROMIS-Anxiety * PROMIS-Fatigue * PROMIS-Sleep related impairment * Pain Number Rating Scale * Generalised Self-Efficiency Scale questionnaire * Multidimensional Health Locus of Control Scale questionnaires Remote follow-up: semi-structured interview over the telephone
Receives: Procedure: Neurofeedback

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Difference in nociplastic pain (Visual Analog Scale)

    Difference in nociplastic pain following 10 sessions of neurofeedback, compared to baseline, as measured by a on a 10 point Visual Analog Scale (VAN), from 1 to 10, where 10 is the highest possible pain. Improvement is indicated by a reduction in score.

    Measured: 4 weeks

Secondary outcomes (9)
  1. Difference in nociplastic pain (ACRFS)

    Difference in nociplastic pain following 10 sessions of neurofeedback, compared to baseline, as measured by the American College of Rheumatology Fibromyalgia Scale (ACRFS). The score ranges between 0-19, with improvement indicated by a reduction in score.

    Measured: 5 weeks

  2. Difference in nociplastic pain (ACRFS) 1 month post-intervention

    Difference in nociplastic pain 1 month after the last session, compared to baseline, as measured by the American College of Rheumatology Fibromyalgia Scale (ACRFS). The score ranges between 0-19, with improvement indicated by a reduction in score.

    Measured: 10 weeks

  3. Success of performing neurofeedback

    EEG power in theta (4-8 Hz), alpha (8-12 Hz) , low beta (13-20 Hz), high beta (20-30) and gamma (30-45 Hz) during NF compared to daily baseline, to assess the success of performing neurofeedback

    Measured: 5 weeks

  4. Mental strategies during neurofeedback

    Self-reported mental strategies (a goal-directed mental action performed in order to control the graphical user interface) and affects (emotional experience e.g.happy, excited, frustrated, anxious etc.) during NF

    Measured: 5 weeks

  5. Multidimensional Health Locus of Control Scale

    Questionnaire that evaluates the quality of life in patients with diseases or disabilities, containing 18 questions or statements. For each statement, the participant rates their level of agreement on a 6 point scale, from strongly disagree, to strongly agree.

    Measured: 6 weeks

  6. NASA task load index

    Questionnaire that rates perceived workload in order to assess the neurofeedback task. The participant rates, on a 20-point visual scale, each of the following aspects: mental demand, physical demand, temporal demand, performance, effort and frustration. Higher scores represent a higher task workload.

    Measured: 5 weeks

  7. 7-Day Symptom Diary

    Pain severity following 10 NF sessions (as measured by 7-Day Symptom Diary (Number Rating Scale between 0-10). A reduction in score represents better outcome.

    Measured: 5 weeks

  8. McGill Pain Questionnaire

    Multidimensional pain questionnaire. Different types of pain are rated from 0-3 (none to severe pain). A reduction in score represents better outcome.

    Measured: 6 weeks

  9. Self-report of adverse events

    Adverse events self-report after each NF session

    Measured: 5 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Feb 2024
  2. Study start24 Jun 2024
  3. Primary completion29 Jan 2027 (estimated)
  4. Study completion29 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
16 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06240299
Sponsor's protocol ID
UGN23NE390
Acronym
NECTAR
Status last verified
Mar 2025
First submitted
6 Dec 2023
Last updated
15 Jun 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Shared on request

Questions about this trial

What is this clinical trial studying?

A study testing Neurofeedback in people with Rheumatoid Arthritis and Chronic Widespread Pain, run by NHS Greater Glasgow and Clyde at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 15 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Aleksandra Vuckovic, PhD (+44 7906441955, aleksandra.vuckovic@glasgow.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Difference in nociplastic pain (Visual Analog Scale) (time frame: 4 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in